Jeanelle King, PA-C
Mount Sinai Comprehensive Cancer Center, Miami Beach, FLAuthored Items
November 2019 Vol 10, No 11
Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/Kāmutant stage III melanoma.
Last modified: November 6, 2019